WNX presents its FY23 Appendix 4E and Initial Financial Statements

Wellnex Life Limited (ASX: WNX), a healthcare company with a strong customer-centric focus, has released its FY23 Appendix 4E, revealing an impressive second consecutive year of robust revenue expansion, which it anticipates will persist into FY24. The company achieved a remarkable 50% increase in Sales Revenue, reaching AU$27.9 million (compared to AU$18.6 million in FY22).

Other key highlights from the report include EBITDA loss remaining consistent with FY22 at AU$6.8 million, while the underlying EBITDA loss stood at approximately AU$5 million, with specific adjustments yet to be clarified. Gross Margins for FY23 were recorded at 17%. The Statutory Loss Before Tax amounted to AU$13.9 million, including a non-cash impairment charge of AU$5.6 million, with total assets as of June 30, 2023, amounting to AU$15.0 million.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com